Education
About Us
Working with TipRanks
Follow Us
Biosergen AB (DE:8N1)
FRANKFURT:8N1
8N1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.02 - €0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)333.00
Market Cap
€9.94M
Enterprise Value€71.70M
Total Cash (Recent Filing)€44.76M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.01
Next Earnings
Nov 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding234,823,210
10 Day Avg. Volume0
30 Day Avg. Volume333
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Biosergen AB News
8N1 FAQ
What was Biosergen AB’s price range in the past 12 months?
Biosergen AB lowest stock price was €0.02 and its highest was €0.09 in the past 12 months.
What is Biosergen AB’s market cap?
Biosergen AB’s market cap is €9.94M.
When is Biosergen AB’s upcoming earnings report date?
Biosergen AB’s upcoming earnings report date is Nov 19, 2025 which is in 62 days.
How were Biosergen AB’s earnings last quarter?
Biosergen AB released its earnings results on Aug 20, 2025. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of -€0.002 by -€0.002.
Is Biosergen AB overvalued?
According to Wall Street analysts Biosergen AB’s price is currently Overvalued.
Does Biosergen AB pay dividends?
Biosergen AB does not currently pay dividends.
What is Biosergen AB’s EPS estimate?
Biosergen AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosergen AB have?
Biosergen AB has 234,823,210 shares outstanding.
What happened to Biosergen AB’s price movement after its last earnings report?
Biosergen AB reported an EPS of -€0.004 in its last earnings report, missing expectations of -€0.002. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biosergen AB?
Currently, no hedge funds are holding shares in DE:8N1
Company Description
Biosergen AB
Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and is headquartered in Solna, Sweden.
Technical Analysis
Alzinova AB
―
Nanologica AB
―
Lipigon Pharmaceuticals AB
―
NextCell Pharma AB
―
Spago Nanomedical AB
―